Thrombotic Thrombocytopenic Purpura (TTP) Global Market Report 2025

The thrombotic thrombocytopenic purpura (TTP) market size has grown strongly in recent years. It will grow from $1.0 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to increased awareness of rare blood disorders, a rising prevalence of autoimmune diseases associated with secondary TTP, advancements in immunosuppressive drug formulations, global growth in healthcare infrastructure, a stronger emphasis on patient education programs for chronic diseases, and the introduction of care guidelines for TTP by health organizations.

The thrombotic thrombocytopenic purpura (TTP) market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The projected growth in the forecast period can be attributed to increased investment in rare disease research, higher government funding for rare disease treatments, growing use of AI and machine learning in diagnosing rare conditions, an expanding geriatric population, and a rising prevalence of cardiovascular diseases. Key trends during this period include the development of recombinant ADAMTS13 enzyme therapies for improved disease management, the growing adoption of biosimilar drugs to lower treatment costs, the use of next-generation sequencing and advanced lab techniques for accurate diagnosis, the implementation of AI tools for early detection of TTP and differentiation from other thrombotic disorders, the creation of individualized treatment approaches based on patient-specific profiles, and both government and private sector investments in rare disease research initiatives.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the thrombotic thrombocytopenic purpura (TTP) market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The rise in these diseases is linked to factors such as an aging population, poor diets, lack of physical activity, obesity, smoking, excessive alcohol consumption, and higher stress levels. Thrombotic thrombocytopenic purpura (TTP) contributes to cardiovascular issues by causing widespread microvascular thrombosis, endothelial dysfunction, and systemic inflammation, all of which increase the risk of hypertension, myocardial infarction, and other cardiovascular complications. For example, in December 2023, the Australian Institute of Health and Welfare, a government agency, reported that deaths from coronary heart disease (CHD) rose to 14,900 in 2022, up from 14,100 in 2021. This increase highlights the impact of cardiovascular diseases, which is driving the growth of the TTP market.

The rise in healthcare spending is also expected to boost the thrombotic thrombocytopenic purpura (TTP) market. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, all aimed at improving or maintaining health. Factors such as an aging population, advances in medical technology, the rising prevalence of chronic diseases, and greater demand for healthcare services contribute to higher healthcare spending. This spending supports the TTP market by enabling better access to advanced diagnostics, life-saving treatments such as plasma exchange and immunosuppressive therapy, ongoing patient monitoring, and research into new therapies, which ultimately improve patient outcomes and reduce complications. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a 0.9% growth in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. This rise in healthcare spending is contributing to the growth of the TTP market.

Companies in the TTP market are focusing on developing innovative therapies, such as recombinant enzyme replacement therapy, to improve treatment outcomes and efficacy. Recombinant enzyme replacement therapy involves administering synthetic or bioengineered enzymes to patients with enzyme deficiencies, restoring normal metabolic function. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based company, introduced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy that was approved by the U.S. Food and Drug Administration (FDA). This is the first and only treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in both adult and pediatric patients. cTTP is a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. Clinical trials supporting ADZYNMA's approval showed that the therapy effectively reduced the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Major players in the thrombotic thrombocytopenic purpura (ttp) market are Pfizer Inc., Merck & Co. Inc., Carelon Research, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Astellas Pharma, Novartis AG, Eisai Co. Ltd., Octapharma AG, Kite Pharma, Medscape, Omeros Corporation, Rigel Pharmaceuticals Inc.

North America was the largest region in the thrombotic thrombocytopenic purpura (TTP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombotic thrombocytopenic purpura (TTP) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombotic thrombocytopenic purpura (TTP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening blood disorder that involves the formation of small blood clots (thrombi) within blood vessels throughout the body. These clots can obstruct blood flow to different organs, potentially causing organ damage. The primary treatment for TTP is plasmapheresis, which removes harmful antibodies and replaces the deficient ADAMTS13 enzyme.

The primary types of thrombotic thrombocytopenic purpura (TTP) are inherited and acquired TTP. Inherited TTP is a rare genetic condition caused by mutations in the ADAMTS13 gene, resulting in impaired breakdown of von Willebrand factor and recurrent clotting episodes. Treatment options for TTP include plasma exchange, corticosteroids, rituximab, caplacizumab, and other therapies. These treatments are used by a variety of end-users, such as hospitals, specialty centers, and other healthcare facilities.

The thrombotic thrombocytopenic purpura (TTP) market research report is one of a series of new reports that provides thrombotic thrombocytopenic purpura (TTP) market statistics, including the thrombotic thrombocytopenic purpura (TTP) industry global market size, regional shares, competitors with the thrombotic thrombocytopenic purpura (TTP) market share, detailed thrombotic thrombocytopenic purpura (TTP) market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombotic thrombocytopenic purpura (TTP) industry. This thrombotic thrombocytopenic purpura (TTP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thrombotic thrombocytopenic purpura (TTP) market consists of revenues earned by entities by providing services such as diagnostic services, immunosuppressive therapy, hospitalization & intensive care services, patient support programs, long-term management and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombotic thrombocytopenic purpura (TTP) market also includes sales of immunosuppressants, plasma-based therapies, monoclonal antibodies, and supportive care treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.